IBT is developing monoclonal antibody (mAb) therapeutics for staphylococcus enterotoxin B (SEB) exposure. IBT and its partner companies have identified a set of anti-SEB mAb leads with remarkable affinity, potency, and therapeutic protection in animal models.
IBT’s SEB mAb lead series has shown efficacy in mouse and macaque models of SEB intoxication. The mAbs appear safe in studies to date. Backup leads have also been identified.
The goal of IBT’s SEB antibody program is to develop an immunotherapy with primary indications for therapy and post-exposure prophylaxis of SEB intoxication in the event of bioterrorism or accidental exposure. The next step in our SEB mAb program is to conduct further characterization and evaluation of the candidates, to select a single mAb or cocktail to advance toward IND and clinical trials.